# Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

> **NCT00071422** · PHASE2 · COMPLETED · sponsor: **Exsulin Corporation** · enrollment: 126 (actual)

## Conditions studied

- Diabetes Mellitus, Non-Insulin-Dependent

## Interventions

- **DRUG:** INGAP-Peptide
- **DRUG:** INGAP-Peptide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00071422
- **Lead sponsor:** Exsulin Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2004-06
- **Final completion:** 2004-06
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2014-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00071422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00071422, "Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00071422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*